The Induction of microRNA-16 in Colon Cancer Cells by Protein Arginine Deiminase Inhibition Causes a p53-Dependent Cell Cycle Arrest

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Cui, Xiangli ^a,b   Witalison, Erin E ^a   Chumanevich, Alena P ^a   Chumanevich, Alexander A ^a   Poudyal, Deepak ^a   Subramanian, Venkataraman ^c   Schetter, Aaron J ^d   Harris, Curtis C ^d   Thompson, Paul R ^c   Hofseth, Lorne J ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOR AMIDINE; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; CYCLIN E1; ENZYME INHIBITOR; MICRORNA 16; PROTEIN ARGININE DEIMINASE; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; PROTEIN FUNCTION; UPREGULATION;

AMIDINES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIN D; CYCLIN E; CYCLIN-DEPENDENT KINASE 6; ENZYME INHIBITORS; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROLASES; MICRORNAS; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872156834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053791     Document Type: Article

References (52)

1. Chang X, Han J, Pang L, Zhao Y, Yang Y, et al. (2009) Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer 9: 40.
2. Jones JE, Causey CP, Knuckley B, Slack-Noyes JL, Thompson PR, (2009) Protein arginine deiminase 4 (PAD4): Current understanding and future therapeutic potential. Curr Opin Drug Discov Devel 12: 616-627.
3. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ, (2003) PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25: 1106-1118.
4. Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, et al. (2011) Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am 300: G929-938.
5. Makrygiannakis D, Klint E, Lundberg IE, Lofberg R, Ulfgren AK, et al. (2006) Citrullination is an inflammation-dependent process. Ann Rheum Dis 65: 1219-1222.
6. Chang X, Han J, (2006) Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors. Mol Carcinog 45: 183-196.
7. Mohanan S, Cherrington BD, Horibata S, McElwee JL, Thompson PR, et al. (2012) Potential role of peptidylarginine deiminase enzymes and protein citrullination in cancer pathogenesis. Biochem Res Int 2012: 895343.
8. Slack JL, Causey CP, Thompson PR, (2011) Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell Mol Life Sci 68: 709-720.
9. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
10. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, et al. (2005) Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120: 21-24.
11. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
12. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529.
13. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, et al. (2009) miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 5553-5559.
14. Klein U, Lia M, Crespo M, Siegel R, Shen Q, et al. (2010) The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17: 28-40.
15. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, et al. (2008) The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 14: 1271-1277.
16. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, et al. (2012) Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 14: R77.
17. Porkka KP, Ogg EL, Saramaki OR, Vessella RL, Pukkila H, et al. (2011) The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer 50: 499-509 doi:410.1002/gcc.20873.
18. Young LE, Moore AE, Sokol L, Meisner-Kober N, Dixon DA, (2012) The mRNA stability factor HuR inhibits microRNA-16 targeting of COX-2. Mol Cancer Res 10: 167-180.
19. Cai CK, Zhao GY, Tian LY, Liu L, Yan K, et al. (2012) miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma. Oncol Rep 28: 1764-1770 doi: 1710.3892/or.2012.1995.
20. Linsley PS, Schelter J, Burchard J, Kibukawa M, Martin MM, et al. (2007) Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 27: 2240-2252.
21. Rissland OS, Hong SJ, Bartel DP, (2011) MicroRNA destabilization enables dynamic regulation of the miR-16 family in response to cell-cycle changes. Mol Cell 43: 993-1004.
22. Wu G, Yu F, Xiao Z, Xu K, Xu J, et al. (2011) Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer 105: 146-153 doi: 110.1038/bjc.2011.1190.
23. Ofir M, Hacohen D, Ginsberg D, (2011) MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res. 9: 440-447.
24. Wang F, Fu XD, Zhou Y, Zhang Y, (2009) Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep 42: 725-730.
25. Takeshita F, Patrawala L, Osaki M, Takahashi RU, Yamamoto Y, et al. (2010) Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther 18: 181-187.
26. Lerner M, Harada M, Loven J, Castro J, Davis Z, et al. (2009) DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res 315: 2941-2952.
27. Li P, Yao H, Zhang Z, Li M, Luo Y, et al. (2008) Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol 28: 4745-4758. Epub 2008 May 4727.
28. Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, et al. (2006) Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry 45: 11727-11736.
29. Causey CP, Thompson PR, (2008) An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4). Tetrahedron Lett 49: 4383-4385.
30. Ying L, Hofseth AB, Browning DD, Nagarkatti M, Nagarkatti PS, et al. (2007) Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res 67: 9286-9293.
31. Wu WK, Law PT, Lee CW, Cho CH, Fan D, et al. (2011) MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 32: 247-253.
32. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, et al. (2009) Modulation of microRNA processing by p53. Nature 460: 529-533.
33. Liu Q, Fu H, Sun F, Zhang H, Tie Y, et al. (2008) miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res 36: 5391-5404.
34. Biggar KK, Storey KB, (2012) Evidence for cell cycle suppression and microRNA regulation of cyclin D1 during anoxia exposure in turtles. Cell Cycle 11: 1705-1713.
35. Balakrishnan A, Stearns AT, Park PJ, Dreyfuss JM, Ashley SW, et al. (2010) MicroRNA mir-16 is anti-proliferative in enterocytes and exhibits diurnal rhythmicity in intestinal crypts. Exp Cell Res 316: 3512-3521.
36. Guo CJ, Pan Q, Jiang B, Chen GY, Li DG, (2009) Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis 14: 1331-1340.
37. Fujisaki M, Sugawara K, (1981) Properties of peptidylarginine deiminase from the epidermis of newborn rats. J Biochem 89: 257-263.
38. Chumanevich AA, Poudyal D, Cui X, Davis T, Wood PA, et al. (2010) Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. Carcinogenesis 31: 1787-1793.
39. Cui X, Jin Y, Hofseth AB, Pena E, Habiger J, et al. (2010) Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res 3: 549-559.
40. Lennard-Jones JE, Morson BC, Ritchie JK, Williams CB, (1983) Cancer surveillance in ulcerative colitis. Experience over 15 years. Lancet 2: 149-152.
41. Ransohoff DF, (1988) Colon cancer in ulcerative colitis. Gastroenterology 94: 1089-1091.
42. Katsanos KH, Vermeire S, Christodoulou DK, Riis L, Wolters F, et al. (2007) Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion 75: 113-121.
43. Wang K, Li P, Dong Y, Cai X, Hou D, et al. (2011) A microarray-based approach identifies ADP ribosylation factor-like protein 2 as a target of microRNA-16. J Biol Chem 286: 9468-9476.
44. Pothof J, Verkaik NS, Van IW, Wiemer EA, Ta VT, et al. (2009) MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response. Embo J 28: 2090-2099.
45. Knuckley B, Causey CP, Jones JE, Bhatia M, Dreyton CJ, et al. (2010) Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry 49: 4852-4863.
46. Chen C, Mendez E, Houck J, Fan W, Lohavanichbutr P, et al. (2008) Gene expression profiling identifies genes predictive of oral squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 17: 2152-2162.
47. Cherrington BD, Zhang X, McElwee JL, Morency E, Anguish LJ, et al. (2012) Potential role for PAD2 in gene regulation in breast cancer cells. PLoS One 7: e41242 doi: 41210.41371/journal.pone.0041242.
48. Li P, Wang D, Yao H, Doret P, Hao G, et al. (2010) Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 29: 3153-3162.
49. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, et al. (2004) Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 306: 279-283.
50. Cuthbert GL, Daujat S, Snowden AW, Erdjument-Bromage H, Hagiwara T, et al. (2004) Histone deimination antagonizes arginine methylation. Cell 118: 545-553.
51. Guo Q, Fast W, (2011) Citrullination of inhibitor of growth 4 (ING4) by peptidylarginine deminase 4 (PAD4) disrupts the interaction between ING4 and p53. J Biol Chem 286: 17069-17078.
52. Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, et al. (2011) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7: 285-295.